CDK4 and breast cancer: We used IT treatments in combination with systemic therapies according to the underlying BC subtype: 88 patients (80.7%) received systemic chemotherapy combined with IT, and 26 patients (23.8%) received endocrine therapy, including 10 patients treated with a CDK4/6 inhibitor.